MASTERINVEST Kapitalanlage GmbH Makes New Investment in Danaher Corporation $DHR

MASTERINVEST Kapitalanlage GmbH bought a new position in Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 8,838 shares of the conglomerate’s stock, valued at approximately $1,746,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. WFA of San Diego LLC purchased a new stake in shares of Danaher during the second quarter worth $26,000. Howard Hughes Medical Institute bought a new stake in shares of Danaher during the 2nd quarter valued at $27,000. Red Tortoise LLC raised its stake in shares of Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the period. Ramirez Asset Management Inc. purchased a new stake in Danaher during the 2nd quarter worth about $40,000. Finally, Twin Peaks Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter worth about $51,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 2.4%

Shares of NYSE:DHR opened at $226.70 on Monday. The firm has a market capitalization of $160.13 billion, a PE ratio of 46.74, a price-to-earnings-growth ratio of 4.39 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The firm has a fifty day moving average of $218.51 and a 200 day moving average of $205.90.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 earnings per share. As a group, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group initiated coverage on Danaher in a research report on Tuesday, December 9th. They set a “buy” rating and a $265.00 price target on the stock. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Redburn Partners set a $220.00 price target on shares of Danaher in a report on Wednesday, October 8th. Barclays upped their price target on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Finally, Cowen reissued a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $246.79.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 in the last 90 days. 11.20% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.